CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

202155Orig1s000

REMS

Initial REMS Approval Date: 12/2012

NDA 202155

ELIQUIS® (apixaban) tablets

Factor Xa Inhibitor

Bristol-Myers Squibb Company
Research & Development
777 Scudders Mill Road
Plainsboro, NJ 08536
United States of America

Contact Information:
Phone: 609-897-5854
Fax: 609-897-3627

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL

The goal of the ELIQUIS REMS is to inform healthcare providers (HCPs) about:

- the increased risk of thrombotic events, including stroke, in patients with nonvalvular atrial fibrillation when discontinuing ELIQUIS without introducing an adequate alternative anticoagulant
- the importance of following the recommendations in the US Prescribing Information (USPI) on how to convert patients with nonvalvular atrial fibrillation from ELIQUIS to warfarin or other anticoagulants.

II. REMS ELEMENTS

A. Communication Plan

Bristol-Myers Squibb will implement a communication plan to HCPs to support implementation of this REMS.

1. Dear Healthcare Professional Letter

A Dear Healthcare Professional (DHCP) Letter will be distributed by direct mail or electronic delivery to HCPs including: cardiologists, neurologists, emergency medicine physicians, internal medicine physicians, primary care physicians, nurse practitioners, physician assistants, and pharmacists. The letter will be distributed within 60 days of approval of ELIQUIS. Annual letters will be sent within 60 days of the anniversary date of approval for ELIQUIS every year for two additional years and within 60 days of FDA approval of any substantial safety update. The DHCP Letter will also be provided to FDA MedWatch at these times. A copy of the USPI and Medication Guide will accompany the DHCP Letter.

In addition, the DHCP Letter, USPI and Medication Guide will also be available on the ELIQUIS REMS website and upon request.

The DHCP letter is part of the REMS and is appended.

2. ELIQUIS REMS Website

Within 30 days of REMS approval, Bristol-Myers Squibb will post information for HCPs and patients on the ELIQUIS REMS website (http://www.ELIQUISREMS.com). This information will remain on the website for a period of 2 years.

The content of the print or web-based material will include the following:

- Goal of the REMS
- Information about the risk
- US Prescribing Information for ELIQUIS
- Medication Guide for ELIQUIS
- DHCP Letter (for a period of 2 years)

The ELIQUIS REMS website is part of the REMS and is appended.

3. Letters to Professional Organizations

A Professional Organization Letter will be distributed by direct mail or electronic delivery within 60 days of the REMS approval date. This communication to professional organizations will include the same information as that contained in the DHCP Letter. Bristol-Myers Squibb will request that these organizations disseminate this information to their members. Bristol-Myers Squibb will communicate the letter to the leadership of the following professional organizations:

- American Heart Association (AHA)
- American College of Cardiologists (ACC)
- Heart Rhythm Society (HRS)
- Society for Cardiovascular Angiography and Interventions (SCAI)
- American Academy of Neurology (AAN)
- American Neurological Association (ANA)
- National Institute of Neurological Disorders and Stroke (NINDS)
- American Stroke Association (ASA)
- National Stroke Association (NSA)
- American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
- Association of Emergency Physicians (AEP)
- American College of Chest Physicians (ACCP)
- Association of Black Cardiologists (ABC)
- American Academy of Family Physicians (AAFP)
- American College of Physicians (ACP)
- Society of General Internal Medicine (SGIM)
- National Medical Association (NMA)
- American Academy of Nurse Practitioners (AANP)
- American Academy of Physician Assistants (AAPA)
- American College of Clinical Pharmacy (ACCP)
- American Society of Health-System Pharmacists (ASHP)
- American Pharmacists Association (APhA)

- National Association of Chain Drug Stores (NACDS)
- American Association of Critical-Care Nurses (AACN)
- National Association of Clinical Nurse Specialists (NACNS)

The USPI and the Medication Guide will be provided in conjunction with the letter.

The Professional Organization Letter is part of the REMS and is appended.

B. Timetable for Submission of Assessments

Bristol-Myers Squibb will submit REMS Assessments to the FDA at 18 months, 3 years, and 7 years from the date of the REMS approval. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Bristol-Myers Squibb will submit each assessment so that it will be received by the FDA on or before the due date.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.